Pharming Group ADR PHAR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
-
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
-
Pharming Group N.V. (PHAR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
-
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
-
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
-
Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)
-
Pharming Group Falls on FDA Letter Requesting Additional Data
Trading Information
- Previous Close Price
- $9.63
- Day Range
- $9.31–9.52
- 52-Week Range
- $9.31–21.13
- Bid/Ask
- $9.32 / $14.08
- Shares Outstanding
- 70.78M
- Market Cap
- $662.48M
- Volume/Avg
- 9,029 / 22,584
Key Statistics
- Price/Earnings (Normalized)
- 53.38
- Price/Sales
- 1.93
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 409
- Website
- https://www.pharming.com
Valuation
|
Metric
|
PHAR
|
|---|---|
Price/Earnings (Normalized) | 53.38 |
Price/Book Value | 2.47 |
Price/Sales | 1.93 |
Price/Cash Flow | 19.49 |
Price/Earnings
PHAR
Financial Strength
|
Metric
|
PHAR
|
|---|---|
Quick Ratio | 2.31 |
Current Ratio | 3.01 |
Interest Coverage | 1.92 |
Quick Ratio
PHAR
Profitability
|
Metric
|
PHAR
|
|---|---|
Return on Assets (Normalized) | 4.18% |
Return on Equity (Normalized) | 7.52% |
Return on Invested Capital (Normalized) | 7.55% |
Return on Assets
PHAR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|D^YrL@B | LOCK|gjHHh | $127B | |||
| Moderna Inc
MRNA
| LOCK|w<#lmbb | LOCK|@>v | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|g?cbJ$ | LOCK|h^FV | $81B | |||
| argenx SE ADR
ARGX
| LOCK|X^^^qZx | LOCK|j< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?>KtlNn | LOCK|?RT | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cW&!%K | LOCK|MHzJ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?PZv!>X | LOCK|XyNMZ | $27B | |||
| Incyte Corp
INCY
| LOCK|r>Q$$S | LOCK|?QK | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|cpt@$k | LOCK|W#L | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@cF#gm | LOCK|>@ | $14B |
United States